Kaiwu Capital, a China-based, early-stage venture capital firm with offices in Beijing and Shanghai, is in the market for a $150 million fund, according to an SEC filing.

The firm – which lists a Cayman Islands address – lists just two of its four partners on the filing: managing partner Shuhua Zhou and partner Karen Liu.

Shuhua Zhou, who has a bachelor’s degree from Xi’an University of Technology and attended Stanford Business School, was until last year a managing director at Northern Light Venture Capital, a China-focused venture firm with offices in Beijing, Shanghai, and Menlo Park. Zhou joined the firm, which has raised $875 million since its founding in 2005, in 2006.

Before Northern Light, Zhou spent six years as a VP at the China-focused online media company SINA Corp., where he led the search and e-commerce business unit.

Meanwhile, Liu’s bio at Kaiwu’s site states that she was previously a managing director at the seven-year-old firm China Renaissance Capital Investment (or CRCI Capital), where she focused on healthcare and life-science related investments.

Liu was also a co-founder and angel investor in Shenogen Pharma, a drug discovery and development company, and a “key senior management member” of 3721.com, a Hong Kong-based company that developed software for keyword searches and that was acquired by Yahoo in 2003.

Liu has both a PhD in immunology and an MMS from Harvard. She also has an undergraduate degree from Cornell and an executive MBA degree from the Chung Kong Graduate School of Business in Beijing.

Kaiwu was founded in early 2011. The firm’s site already lists 17 portfolio companies, too, including Sagent Pharma, a generic injectable drug maker in Schaumburg, Ill. that went public on Nasdaq in April of last year. (The investment is listed by Liu as “among her life science portfolio.”) Other investments include several Internet investments, such as Kaixin001, a China-focused social network; LineKong, an online game publisher in China; and Hudong, a Wikipedia-like company; along with numerous medical device and drug development companies

Update: Kaiwu did not invest directly in the companies in the portfolio section of its site, points out Jeffrey Lee, a managing director at Northern Light Venture Capital. He writes, “These are companies that the members of this firm may take credit for their involvement at their previous firms.” Kaixin001, LineKong, and Hudong are all investments of Northern Light , for example, not of Kaiwu,  ”although members of Kaiwu may have been involved in these investments when they were at Northern Light.”

Kaiwu’s new SEC filing is apparently its first, though a year-old article about one of the firm’s advisors suggests that the firm has probably been feeling out potential investors since its launch.

Photo: Image courtesy of Shutterstock.